menu
    • menu
    [{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Celyad","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"CYAD-101","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Genome & Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"GEN-001","moa":"||IL-7","graph1":"Oncology","graph2":"IND Enabling","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"5","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"HER-Vaxx","moa":"HER2","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Ionova Life Science","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"INV-1120","moa":"EP4","graph1":"Oncology","graph2":"Phase I","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AUM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"AUM001","moa":"MNK1\/2","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Novocure","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"PD-L1","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Opevesostat","moa":"CYP11A1","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"7","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Genexine","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Vaccine","year":"2022","type":"Not Applicable","leadProduct":"GX-188E","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Nykode Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"VB10.16","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"PharmAbcine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"PMC-309","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Zhejiang Doer Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"DR30303","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Antengene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"ATG-037","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"6","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Nouscom AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"GAd20-209-FSP","moa":"","graph1":"Oncology","graph2":"Phase II","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"8","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"Curve Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Small molecule","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"HIF-1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MSD Pharmaceuticals","amount2":1.7,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"MSD Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Antibody-drug Conjugate","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"MSD Pharmaceuticals","amount2":0.93999999999999995,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0.93999999999999995,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"PeptiDream","pharmaFlowCategory":"D","therapeuticArea":"Technology","country":"JAPAN","productType":"Peptide","year":"2022","type":"Collaboration","leadProduct":"Peptide-drug Conjugate","moa":"","graph1":"Technology","graph2":"Discovery Platform","graph3":"MSD Pharmaceuticals","amount2":2.1000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Technology","amount2New":2.1000000000000001,"dosageForm":"","sponsorNew":"MSD Pharmaceuticals \/ MSD Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"MSD Pharmaceuticals \/ MSD Pharmaceuticals"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD"},{"orgOrder":0,"company":"MSD Pharmaceuticals","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Cytotoxic Drug","year":"2022","type":"Inapplicable","leadProduct":"Olaparib","moa":"||PARP 1\/2\/3","graph1":"Oncology","graph2":"Approved FDF","graph3":"MSD Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"MSD Pharmaceuticals \/ MSD","highestDevelopmentStatusID":"15","companyTruncated":"MSD Pharmaceuticals \/ MSD"}]

    Find Clinical Drug Pipeline Developments & Deals by MSD Pharmaceuticals

    Menu

    MSD Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Recipient : Nouscom AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nouscom Announces Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate NOUS-209 in combinati...

                            Details : NOUS-209 (GAd20-209-FSP) is an off-the-shelf cancer immunotherapy for MSI-H tumors. MSI-H tumors are characterized by a defective DNA mismatch repair system, which generates highly immunogenic neoantigens called frame shift peptides that are not present ...

                            Product Name : NOUS-209

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 05, 2023

                            Lead Product(s) : GAd20-209-FSP,MVA-209-FSP,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Recipient : Nouscom AG

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Peptide-drug Conjugate

                            Therapeutic Area : Technology

                            Study Phase : Discovery Platform

                            Recipient : PeptiDream

                            Deal Size : $2,100.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PeptiDream Announces Collaboration and License Agreement with MSD for the Discovery and Development of Novel P...

                            Details : Under the agreement, PeptiDream will provide peptide candidates identified from PeptiDream’s proprietary Peptide Discovery Platform System (“PDPS”) technology for use as PDCs against targets of interest to MSD.

                            Product Name : Undisclosed

                            Product Type : Peptide

                            Upfront Cash : Undisclosed

                            December 27, 2022

                            Lead Product(s) : Peptide-drug Conjugate

                            Therapeutic Area : Technology

                            Highest Development Status : Discovery Platform

                            Recipient : PeptiDream

                            Deal Size : $2,100.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATG-037,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Antengene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-037 (CD73 Inhibitor) in Combina...

                            Details : ATG-037 is an oral, small molecule CD73 inhibitor. CD73 generates adenosine, which leads to immunosuppression in the tumor microenvironment. ATG-037 has demonstrated promising preclinical efficacy as a monotherapy and in combination with ICIs and chemoth...

                            Product Name : ATG-037

                            Product Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 26, 2022

                            Lead Product(s) : ATG-037,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Antengene

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olaparib,Abiraterone Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lynparza in Combination with Abiraterone Approved in The EU as 1st-Line Treatment for Patients with Metastatic...

                            Details : Lynparza (olaparib) is a first-in-class PARP inhibitor and the first targeted treatment to block DNA damage response (DDR) in cells/tumours harbouring a deficiency in HRR, such as those with mutations in BRCA1 and/or BRCA2, or those where deficiency is i...

                            Product Name : Lynparza

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 21, 2022

                            Lead Product(s) : Olaparib,Abiraterone Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : DR30303,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Zhejiang Doer Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Zhejiang Doer Biologics Announces Clinical Trial Collaboration with MSD to Evaluate DR30303 in Combination wit...

                            Details : DR30303 is a humanized anti-Claudin18.2 heavy chain antibody Fc fusion protein (VHH-Fc) generated via Doer Biologics' proprietary SMART-VHHBody platform.

                            Product Name : DR30303

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 15, 2022

                            Lead Product(s) : DR30303,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Zhejiang Doer Biologics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olaparib,Abiraterone Acetate

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Update on US Regulatory Priority Review of Lynparza in Combination with Abiraterone in Metastatic Castration-R...

                            Details : LYNPARZA (olaparib), is a first-in-class PARP inhibitor and the first targeted treatment to potentially exploit DNA damage response (DDR) pathway deficiencies, such as BRCA mutations, to preferentially kill cancer cells.

                            Product Name : Lynparza

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            December 15, 2022

                            Lead Product(s) : Olaparib,Abiraterone Acetate

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : PMC-309,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : PharmAbcine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            PharmAbcine Announces Collaboration Agreement with MSD to Evaluate Anti-VISTA Antibody PMC-309 in Combination ...

                            Details : PMC-309 is a novel IgG1 anti-VISTA antagonizing antibody that can be used for the treatment of various tumor types. By inhibiting VISTA, it can play a pivotal role in maintaining the immunosuppressive environment around the tumor cells.

                            Product Name : PMC-309

                            Product Type : Large molecule

                            Upfront Cash : Undisclosed

                            December 12, 2022

                            Lead Product(s) : PMC-309,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : PharmAbcine

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : VB10.16,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Recipient : Nykode Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nykode Therapeutics Announces Clinical Collaboration with MSD to Evaluate VB10.16 in Combination With KEYTRUDA...

                            Details : VB10.16 is an off-the-shelf therapeutic cancer vaccine specifically designed to treat HPV16-induced malignancies. Under the terms of the agreement, Merck will supply KEYTRUDA. Nykode retains all commercial rights to VB10.16 worldwide.

                            Product Name : VB10.16

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            December 06, 2022

                            Lead Product(s) : VB10.16,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Recipient : Nykode Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olaparib,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lynparza in Combination With Abiraterone Recommended for Approval in the EU by CHMP As 1st-line Treatment for ...

                            Details : Lynparza (olaparib) is first-in-class PARP inhibitor and first targeted treatment to block DNA damage response in cells/tumours harboring deficiency in HRR.

                            Product Name : Lynparza

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            November 14, 2022

                            Lead Product(s) : Olaparib,Abiraterone Acetate,Prednisone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed

                            MSD Pharmaceuticals

                            India arrow
                            ELCC
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olaparib,Bevacizumab

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lynparza Approved In China As 1st-line Maintenance Treatment With Bevacizumab For HRD-positive Advanced Ovaria...

                            Details : The approval by CNMPA was based on HRD-positive subgroup exploratory analysis of PAOLA-1 Phase III trial which showed Lynparza (olaparib) plus bevacizumab demonstrated a substantial PFS improvement versus bevacizumab for patients with HRD-positive advanc...

                            Product Name : Lynparza

                            Product Type : Cytotoxic Drug

                            Upfront Cash : Inapplicable

                            September 22, 2022

                            Lead Product(s) : Olaparib,Bevacizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : AstraZeneca

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth